Technology ID
TAB-3555
Mutant IDH1 Inhibitors for Anticancer Therapy
E-Numbers
E-189-2016-0
Lead Inventor
Boxer, Matthew (NCATS)
Co-Inventors
Rohde, Jason (NCATS)
Pragani, Rajan (NCATS)
Liu, Li (NCATS)
Davis, Mindy (NCATS)
Brimacombe, Kyle (NCATS)
Shen, Min (NCATS)
Simeonov, Anton (NCATS)
Karavadhi, Surendra (NCATS)
Jadhav, Ajit (NCATS)
Hall, Matthew (NCATS)
Zhao, Wei (NCATS)
Fang, Yuhong (NCATS)
Martinez, Natalia (NCATS)
Wang, Xiaodong (University of North Carolina, Chapel Hill)
McIver, Andrew (University of North Carolina, Chapel Hill)
Applications
Therapeutics
Therapeutic Areas
Oncology
Lead IC
NCATS
ICs
NCATS
This technology includes mutant isocitrate dehydrogenase (IDH1) inhibitors to be utilized as anticancer therapy. These potent inhibitors are aimed at lowering levels of the oncometabolite–2-hydroxyglutarate.
Commercial Applications
Anticancer agent that targets IDH1 mutations.
Licensing Contact: